Renovaro, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. Its pipeline consists of ENOB-HV-01, ENOB- HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21. The company was founded by Rene Sindlev and Serhat Gumrukcu on January 18, 2011 and is headquartered in Los Angeles, CA.
Clinical Trials
0
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
No trial phase data available
No trial data available
No trial data available
No approval data available
- Lunai Bioworks Inc. (formerly Renovaro Inc.) officially adopted its new corporate identity on September 30, 2025, trading under ticker symbol "LNAI" following a 10:1 reverse stock split. - The company launched a proprietary transformer-based platform that embeds neurotoxicity intelligence into generative AI pipelines for safe compound discovery and biodefense applications. - Through subsidiary BioSymetrics Inc., Lunai advanced a preclinical biomarker discovery program in Parkinson's Disease using phenogrouping and multimodal data analysis. - BioSymetrics secured a multi-year STTR grant from NIH to support platform expansion and validation of their AI-driven therapeutic discovery capabilities.
- Renovaro Biosciences published peer-reviewed preclinical data in Vaccines journal showing their genetically engineered dendritic cell therapy reduced pancreatic tumor burden by up to 81.7% in humanized mouse models. - The therapy uses CD34+ stem cells from healthy donors to create "off-the-shelf" dendritic cells engineered to express CD93, CD40L, and CXCL13 proteins that enhance immune system activation. - Treated animals demonstrated significant increases in CD4+ helper T cells and cytotoxic CD8+ T cells in blood, bone marrow, and tumor microenvironments. - The allogeneic approach addresses manufacturing scalability challenges that have limited previous dendritic cell therapies like Provenge, potentially improving cost structure and market accessibility.
- Renovaro Inc. (NASDAQ:RENB) announced that senior debt holders agreed to convert approximately $9.7 million of outstanding debt into equity through the issuance of 53.6 million shares at $0.30 per share. - The debt conversion significantly enhances the company's balance sheet by eliminating debt obligations and interest payments, providing greater financial flexibility for growth initiatives. - The biotechnology company focuses on AI-driven precision medicine, developing innovative therapies and diagnostics in oncology, infectious disease, and autoimmune disorders using machine learning integrated with biomedical research.
- Renovaro Inc. has launched Augusta, an AI-powered precision neurology platform that integrates multiomics, phenoclustering, and CRISPR screens to accelerate biomarker and drug discovery for neurological disorders. - The platform has already demonstrated efficacy in Parkinson's Disease by identifying novel patient subgroups with unique biomarkers, and in epilepsy by discovering lead compounds for patients with rare genetic mutations. - Augusta addresses key challenges in neurological disorder treatment through advanced data preprocessing, phenoclustering, biomarker identification, in silico screening, and closed-loop validation techniques.
- Predictive Oncology has completed the sale of its Skyline Medical subsidiary to DeRoyal Industries, allowing the company to focus exclusively on its AI-driven drug discovery platform for cancer research. - The transaction transfers the FDA-cleared STREAMWAY® System, a direct-to-drain waste fluid management technology for healthcare settings, to DeRoyal Industries who will continue offering the product under their brand. - This strategic divestiture positions Predictive Oncology for its planned merger with Renovaro Biosciences while enabling the STREAMWAY® technology to expand its market reach through DeRoyal's established healthcare product distribution network.
- Renovaro Biosciences and BioSymetrics have entered into a definitive merger agreement, combining TechBio expertise with AI-driven drug discovery capabilities to advance precision medicine in oncology and other diseases. - BioSymetrics' proprietary Elion platform and Phenograph engine will be integrated into Renovaro's workflow, enabling faster biomarker identification, target validation, and therapeutic development through advanced AI and machine learning. - The merger, expected to close in March 2025, builds on existing partnerships with major pharmaceutical companies and aims to enhance patient stratification and treatment optimization in precision medicine.
